Special drug-use survey of Tarlige (central neuropathic pain)
Not Applicable
Recruiting
- Conditions
- Central neuropathic pain
- Registration Number
- JPRN-jRCT2031220132
- Lead Sponsor
- Matsuoka for Yomei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
(1) Patients with central neuropathic pain not treated with Tarlige before
(2) Patients who started administration of Tarlige during the contract period (contract period based on the contract with each medical site)
(3) Patients who started administration of Tarlige during the registration period
(4) Patients from whom written informed consent was obtained
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of adverse drug reactions stratified by the causative diseases of neuropathic pain
- Secondary Outcome Measures
Name Time Method Change in VAS (Visual Analogue Scale) of pain